Skip to main content
Premium Trial:

Request an Annual Quote

Microarrays in Limbo

The votes are in and it would seem that the research community hasn't quite made up its mind about what to do with microarrays just yet.

In a recent poll conducted by the RNA-Seq Blog, about half of 175 total respondents, or 88 voters, declared that microarrays are here to stay, while the remaining 50 percent, or 87 voters, believe that its time is over.

Earlier this year, Daily Scan's sister publication, BioArray News, reported that the array market has been feeling pressure for some time from the growing availability of increasingly affordable next-generation sequencing-based applications and also weaker government research spending where proposals that explicitly mention a desire to use sequencing are viewed as more likely to secure funding than those that rely on arrays.

But the results of this poll indicate that microarrays "may be here to stay," the RNA-Seq Blog says.

That suggestion is supported by recent comments from Seth Crosby, director of Genome Technology Access Center at Washington University's School of Medicine, who told BioArray News that he continues to see a demand for arrays and predicted that the technology will hold its own for a few more years even though it will likely lose some ground to sequencing technologies.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.